Akili, Inc.

Greetings, and welcome to the Akili fourth quarter 2022 earnings call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Julie DiCarlo, Senior Vice President of Communications.

Thanks, Joe. Good afternoon and welcome to Achilles Earnings Conference Call for the fourth quarter of 2022. After the market closed today, we issued our earnings release, which can be accessed on the investor relations section of our website. Additionally, we've posted earnings slides on our IR website that we'll reference during today's call. This call is being recorded and a replay of the teleconference will be available on our IR website at the conclusion of today's event. During today's call, we'll make forward-looking statements regarding future events, expectations, plans, prospects, or the financial performance of the company. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the company's management, involve certain risks and uncertainties. The company's actual results may differ materially from those expressed or implied by any such forward-looking statements as a result of various important factors, factors that might cause such differences include but are not limited to those risks and uncertainties set forth in our form 10Q filed on November 14th, as well as other subsequent filings with the SEC. Information provided on today's call reflects our views only as of today, March 7th, and should not be relied upon as representative of our views as of any subsequent date. We explicitly disclaim any obligation to update or revise any forward-looking statements or our outlook. Also during today's call, We'll refer to certain non-GAAP financial measures. Management does not intend the presentation of these non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP, but as a complement to provide greater transparency. A reconciliation of the historical non-GAAP financial measures to our GAAP financial measures is included in our earnings slides and in our earnings release. If you're following along with the slides, please turn now to the agenda. With me on today's call are Achilles CEO, Eddie Martucci, our President and Chief Operating Officer, Matt Franklin, our Chief Medical Officer, Scott Collins, and our Chief Financial Officer, Santos Schaumbach. Now please turn to slide four as I hand the call over to Eddie for his prepared remarks. Eddie?

Thanks, Julie. Hello, everyone. Thank you for joining our call to discuss our business performance in Q4 of last year and our overall summary of 2022. Today you'll hear from Matt, Scott, and Santosh on various detailed aspects of our business growth. We're excited about how we're evolving the business and seeing the increasing traction of EndeavorRx and more generally progress of our business model. With moves that we announced in early Q1 of this year to restructure the business, we're now operating with a more efficient capital footprint so that we can execute against our most important business goals and have cash that we expect will fund the business into Q1 2025. With our heightened focus on EndeavorRx and the ADHD marketplace, we'll look to prove out that a digital treatment can indeed scale like a drug. I believe EndeavorRx has the potential to be the first example of this new paradigm, and the entire Akili team is passionate and focused on making that happen. I'm excited with the early impact of our Salesforce investment, where we're seeing a positive increase in most commercial metrics. We're also seeing strong willingness to pay out of pocket by patients. As expected, we haven't seen insurers step up to broader coverage, and this is a continued area of focus for us. And we continue to push the cutting edge of a patient experience in medicine with multiple enhancements to both our treatment product and our caregiver companion product over the last quarter. In terms of getting Endeavor X to all of the ADHD patients we believe can benefit from our product, We were extremely excited to announce positive outcomes from our STARS ADHD adolescent trial earlier than anticipated in January of this year. With the needs around mental health in teens and the ongoing ADHD medication shortage, we're putting urgency around our planned FDA submission this year for review of an expanded label for EndeavorRx to include adolescents over 12 years of age. If successful, that expanded label would essentially double our current addressable market based on our estimates. Overall, I believe we've made good progress to end the year, and I'm even more pleased with our team's increased focus and execution mindset here in the early part of 2023. I'll now turn it over to our President and COO, Matt Franklin, to give you a deeper look into our core business progress. Matt?